TSHA
Price:
$2.04
Market Cap:
$418.08M
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy tr...[Read more]
Industry
Biotechnology
IPO Date
2020-09-24
Stock Exchange
NASDAQ
Ticker
TSHA
According to Taysha Gene Therapies, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 302.61M. This represents a change of -21.58% compared to the average of 385.87M of the last 4 quarters.
The mean historical Enterprise Value of Taysha Gene Therapies, Inc. over the last ten years is 330.78M. The current 302.61M Enterprise Value has changed 9.05% with respect to the historical average. Over the past ten years (40 quarters), TSHA's Enterprise Value was at its highest in in the June 2020 quarter at 836.59M. The Enterprise Value was at its lowest in in the September 2020 quarter at -15810992.00.
Average
330.78M
Median
217.59M
Minimum
71.38M
Maximum
890.04M
Discovering the peaks and valleys of Taysha Gene Therapies, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 71.27%
Maximum Annual Enterprise Value = 890.04M
Minimum Annual Increase = -79.76%
Minimum Annual Enterprise Value = 71.38M
Year | Enterprise Value | Change |
---|---|---|
2023 | 122.25M | 71.27% |
2022 | 71.38M | -79.76% |
2021 | 352.62M | 62.05% |
2020 | 217.59M | -75.55% |
The current Enterprise Value of Taysha Gene Therapies, Inc. (TSHA) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
182.08M
5-year avg
330.78M
10-year avg
330.78M
Taysha Gene Therapies, Inc.’s Enterprise Value is less than Biomea Fusion, Inc. (0), greater than Stoke Therapeutics, Inc. (153.42M), less than Akero Therapeutics, Inc. (586.20M), less than Homology Medicines, Inc. (1.56B), greater than Gossamer Bio, Inc. (-103303255.00), less than X4 Pharmaceuticals, Inc. (317.87M), greater than Inozyme Pharma, Inc. (40.79M), less than Terns Pharmaceuticals, Inc. (343.89M), less than Day One Biopharmaceuticals, Inc. (458.36M), less than HOOKIPA Pharma Inc. (1.01B), greater than Monte Rosa Therapeutics, Inc. (87.25M), greater than Cabaletta Bio, Inc. (284.72M), greater than Larimar Therapeutics, Inc. (36.88M), less than Alector, Inc. (486.93M), less than Shattuck Labs, Inc. (460.58M), greater than C4 Therapeutics, Inc. (110.17M), less than Eliem Therapeutics, Inc. (369.73M), greater than Prelude Therapeutics Incorporated (272.53M), greater than null (257.24M),
Company | Enterprise Value | Market cap |
---|---|---|
0 | $256.37M | |
153.42M | $773.92M | |
586.20M | $1.83B | |
1.56B | $3.02M | |
-103303255.00 | $205.87M | |
317.87M | $109.78M | |
40.79M | $312.42M | |
343.89M | $549.60M | |
458.36M | $1.25B | |
1.01B | $159.50M | |
87.25M | $349.21M | |
284.72M | $208.10M | |
36.88M | $513.64M | |
486.93M | $472.01M | |
460.58M | $167.05M | |
110.17M | $374.42M | |
369.73M | $495.57M | |
272.53M | $266.87M | |
257.24M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Taysha Gene Therapies, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Taysha Gene Therapies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Taysha Gene Therapies, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Taysha Gene Therapies, Inc. (TSHA)?
What is the 3-year average Enterprise Value for Taysha Gene Therapies, Inc. (TSHA)?
What is the 5-year average Enterprise Value for Taysha Gene Therapies, Inc. (TSHA)?
How does the current Enterprise Value for Taysha Gene Therapies, Inc. (TSHA) compare to its historical average?